Eosinophilic Esophagitis Management With PRO Dysphagia Tracking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating eosinophilic esophagitis (EoE) are inadequate due to misdiagnosis with gastroesophageal reflux disease (GERD) and lack of accurate recording of dysphagia episodes, leading to delayed and improper treatment.
Innovation Solution
A method involving patient-reported outcome (PRO) questionnaires to record dysphagia episodes in real-time and measure esophageal eosinophils before and during treatment with therapeutic agents, using corticosteroids, proton pump inhibitors, or antibodies, to reduce dysphagia episodes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If EoE is diagnosed using esophageal biopsies showing 15 or more eosinophils per HPF, then diagnostic accuracy is improved, but treatment delay occurs due to misdiagnosis with GERD
Solution Approach 1:
The patent implements real-time dysphagia episode recording using PRO questionnaires before treatment begins. This preliminary documentation of symptom patterns, frequency, and severity establishes a baseline that enables faster differentiation between EoE and GERD, reducing diagnostic delay while maintaining biopsy-based diagnostic accuracy.
Solution Approach 2:
The patent employs continuous feedback loops where patients record dysphagia episodes in real-time, and clinicians monitor treatment response through symptom reduction. This feedback mechanism allows for rapid confirmation of EoE diagnosis and adjustment of therapy, preventing the treatment delays associated with traditional diagnostic approaches.
2Ease of operation
If dysphagia episodes are recorded using traditional methods, then diagnostic simplicity is maintained, but recording accuracy deteriorates leading to improper treatment
Solution Approach 1:
The patent enables patients to self-record dysphagia episodes using standardized PRO questionnaires. Patients independently document symptom occurrences, timing, and severity in real-time, eliminating reliance on clinician assessment and improving recording accuracy while maintaining operational simplicity through user-friendly tools.
Solution Approach 2:
The patent replaces traditional clinician-dependent diagnostic assessment with automated electronic PRO questionnaires and digital tracking systems. This substitution of mechanical assessment methods with digital tools improves measurement precision while preserving ease of operation through standardized, patient-completed forms.
3Productivity
If treatment is initiated without accurate dysphagia recording, then treatment speed is improved, but treatment efficacy deteriorates
Solution Approach 1:
The patent requires completion of baseline PRO questionnaires and dysphagia episode recording before treatment initiation. This preliminary data collection occurs rapidly and enables clinicians to prescribe appropriate therapy immediately, maintaining treatment speed while ensuring treatment efficacy through accurate baseline characterization of symptom severity and patterns.
Solution Approach 2:
The patent implements continuous monitoring of dysphagia episode frequency and severity during treatment through repeated PRO assessments. This real-time feedback allows clinicians to verify treatment efficacy and adjust therapy as needed, ensuring reliable outcomes while maintaining rapid treatment initiation and progression.
Data Source
AI summary
Described herein are methods of managing eosinophilic esophagitis (EoE) in a patient, wherein the patient records the number of episodes of dysphagia on a patient report outcome (PRO) questionnaire prior to and during the course of treatment. While on treatment, the number of episodes of dysphagia are reduced, as reported on the PRO questionnaire. In some embodiments, the esophageal eosinophils are counted before or after treatment, or both. In some embodiments, esophageal eosinophils counts are not correlated with a reduction in the episodes of dysphagia.